A Study to Assess Efficacy, Safety and Tolerability of the Anti-IL-13 Monoclonal Antibody QAX576 in the Treatment of Perinanal Fistulas in Patients Suffering From Crohn's Disease

Status:
Completed

Trial end date:
2012-11-01

Target enrollment:

Participant gender:

Test safety and efficacy and of a novel IL-13 AB in the treatment of perianal fistulas - Trial with medicinal product

Phase 2

Gerhard Rogler

Novartis Pharmaceuticals